Clinical outcome of advanced EGFR-mutated NSCLC patients who developed acquired resistance to first generation EGFR inhibitors with positive plasma T790M treated with osimertinib in NSW, Australia.

Trial Profile

Clinical outcome of advanced EGFR-mutated NSCLC patients who developed acquired resistance to first generation EGFR inhibitors with positive plasma T790M treated with osimertinib in NSW, Australia.

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Jul 2017

At a glance

  • Drugs Osimertinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms CONTROL
  • Most Recent Events

    • 11 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top